Philippoteaux, C.; Deprez, V.; Nottez, A.; Cailliau, E.; Houvenagel, E.; Deprez, X.; Philippe, P.; Pascart, T.; Flipo, R.-M.; Goëb, V.;
et al. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings. J. Clin. Med. 2023, 12, 207.
https://doi.org/10.3390/jcm12010207
AMA Style
Philippoteaux C, Deprez V, Nottez A, Cailliau E, Houvenagel E, Deprez X, Philippe P, Pascart T, Flipo R-M, Goëb V,
et al. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings. Journal of Clinical Medicine. 2023; 12(1):207.
https://doi.org/10.3390/jcm12010207
Chicago/Turabian Style
Philippoteaux, Cécile, Valentine Deprez, Aurore Nottez, Emeline Cailliau, Eric Houvenagel, Xavier Deprez, Peggy Philippe, Tristan Pascart, René-Marc Flipo, Vincent Goëb,
and et al. 2023. "Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings" Journal of Clinical Medicine 12, no. 1: 207.
https://doi.org/10.3390/jcm12010207
APA Style
Philippoteaux, C., Deprez, V., Nottez, A., Cailliau, E., Houvenagel, E., Deprez, X., Philippe, P., Pascart, T., Flipo, R.-M., Goëb, V., & Letarouilly, J.-G.
(2023). Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings. Journal of Clinical Medicine, 12(1), 207.
https://doi.org/10.3390/jcm12010207